Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Clinical trial NCT03618550 · RECRUITING
Trial details
- NCT number
- NCT03618550
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-01
- Primary completion
- 2027-08-01
- Enrollment
- 257
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.